SHCNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
Sotera Health Co
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$17.64−0.25 (-1.40%)
Close on Oct 19, 2026
- Market cap
- $5.08B
- P/E (TTM)
- 30.9
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
55.5%+1.3 pts over 5 years
Operating margin
–
Net margin
6.7%+11.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.7% | +5.1% | +7.3% | – | |
| Gross profit | +7.2% | +5.0% | +7.8% | – | |
| Net income | +75.6% | – | – | – | |
| EPS, diluted | +68.8% | – | – | – | |
| Free cash flow | +230.8% | +16.0% | +17.3% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 15.4% | |
| Return on assets | – | – | 2.5% | |
| Current ratio | – | 2.24 | 2.46 | |
| Debt to equity | – | 4.03 | 3.53 | |
| Net debt to EBITDA | – | 6.40× | – | |
| Inventory turnover | – | – | 10.0× | |
| Capex to revenue | – | 6.5% | 11.9% | |
| Diluted shares | – | 238M | 286M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Sotera Health generated $1.22B from operations and spent $816.60M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.22B
Used
$816.60M
Capital expenditure$816.60M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin6.7%
×Asset turnover0.37×
×Equity multiplier6.27×
=Return on equity, FY202515.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 6.7% | 0.37× | 6.27× | 15.4% |
| FY2024 | 4.0% | 0.35× | 7.31× | 10.5% |
| FY2023 | 4.9% | 0.34× | 7.87× | 12.9% |
| FY2022 | -23.3% | 0.34× | 6.31× | -49.9% |
| FY2021 | 12.5% | 0.34× | 5.35× | 22.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$77.95M
- Cash generatingOperating cash flow above zero$287.20M
- Return on assets improvedROA up on the prior year1.4% → 2.5%
- Earnings backed by cashOperating cash flow above net income$287.20M vs $77.95M
- Less leverageLong-term debt to assets fell71.9% → 65.2%
- Better liquidityCurrent ratio rose2.75 → 2.46
- No dilutionShare count did not rise285M → 286M
- Gross margin improvedGross margin up on the prior year54.73% → 55.48%
- More efficientAsset turnover rose0.35 → 0.38